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Abstract Study Objectives Stage I adenocarcinoma of the
lung is the most common type of lung cancer. A better
understanding of the histopathology and molecular biology
of lung cancer might improve the capability to predict the
outcome for any individual patient. The purpose of this
study was to evaluate several histopathologic and molecular
markers in order to assess their prognostic value in stage I
adenocarcinoma. Methods Fifty-five patients at the Seoul
National University Bundang Hospital were enrolled in the
study. Histopathologic factors and molecular markers were
selected. Results Multivariate analysis demonstrated that
necrosis, lymphatic vessel invasion, E-cadherin, p53, and
Ki-67 emerged as independent prognostic factors of recur-
rence. When patients were grouped according to low or high
risk according to the number of factors involved, the dif-
ference in disease-free survival between these groups was
statistically significant. Conclusions In resected stage I
adenocarcinoma, necrosis, lymphatic vessel invasion,
E-cadherin, and p53 have been identified as independent
predictors of disease-free survival.
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Introduction
Lung cancer is the most common cause of mortality
worldwide. Non-small-cell lung cancer (NSCLC) accounts
for approximately 80% of lung cancer cases [1], and
pathologic stage I is the fastest growing segment as found
by the use of low-dose computed tomography (LDCT) for
screening. Despite the potential benefits of surgical resec-
tion, patients with pathologic stage I lung cancer display
marked variability in recurrence and survival. Even after
complete resection, the 5-year survival rate of stage I
patients is only 55–72%, predominantly as a result of the
development of distant metastases [2, 3]. Variation in
survival largely reflects heterogeneity in tumor biology,
with some tumors having more aggressive growth and
greater metastatic potential than others; therefore, tumor
stage alone is no longer the primary determinant of prog-
nosis for these patients. New prognostic factors need to be
identified to help clinicians better assess the probability of
survival and optimize therapeutic strategies for each indi-
vidual patient with pathologic stage I lung cancer. A better
understanding of the molecular biology of NSCLC may
help predict the outcome for individual patients, which in
turn would facilitate the definition of subgroups of patients
according to prognosis [4]. Several studies have already
demonstrated possible prognostic roles for several biolog-
ical factors in NSCLC and have found helpful tools for
identifying patients with poor prognosis [5–8]. As a result,
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the stratification of patients, without lymph node involve-
ment, according to prognostic risk might aid in selecting a
group of high-risk patients who would benefit from adju-
vant therapy.
The purpose of this study was to evaluate several his-
topathologic variables and a panel of molecular markers in
order to assess their prognostic value and their combined




Between June 2003 and August 2005, 55 patients (31 male,
24 female) at the Seoul National University Bundang
Hospital (SNUBH) with resected stage I adenocarcinoma
were enrolled in the study. All patients underwent poten-
tially curative surgery consisting of lobectomy (n = 52) or
segmentectomy (n = 3) and complete mediastinal lymph
node dissection. None of the patients had neoadjuvant
therapy. Patients who died within 1 month after surgery
were excluded from the study to avoid the bias of periop-
erative mortality. This study was approved by the
Institutional Review Board of SNUBH.
The age of the patients ranged from 40 to 81 years
(mean = 63.4 years). Postsurgical pathologic TNM stag-
ing was determined according to the guidelines of the
American Joint Cancer Committee (AJCC). There were 28
cases of stage IA (T1N0M0) and 27 cases of stage IB
(T2N0M0). Follow-up data on the study population were
obtained by direct contact. Follow-up occurred at 3-month
intervals for the initial 3 years and at 4-month intervals
thereafter. Recurrences were detected by computed
tomography scans or by positron emission tomography
and, if necessary, confirmed by pathologic examination of
biopsy specimens. Patients were categorized as alive with
evidence of disease or alive without disease. No patient in
this series died of cancer-unrelated causes. Time from the
date of the operation to the date of follow-up or death was
recorded. Local recurrence is defined as tumor recurrence
at the ipsilateral lung or lymph node, and distant recurrence
is defined as tumor recurrence at the contralateral lung or
lymph node and a distant organ such as the liver, brain, or
bone.
Pathologic Criteria
Tumor samples were fixed in 10% buffered formalin,
dehydrated, and embedded in paraffin. Then, 4-ll-thick
sections were cut and stained with hematoxylin and eosin.
Pathologic features were classified according to the
histologic criteria of the World Health Organization. The
degree of differentiation was divided into three groups:
well, moderate, and poor. Tumor vascular invasion (absent
vs. present) and lymphatic vessel invasion (absent vs.
present) were defined as the identification of emboli com-
posed of neoplastic cell aggregates within the tumor vessel
and lymphatic vessel, respectively. Tumor necrosis (nega-
tive, \10%; positive, C10%) and visceral pleural invasion
(absent vs. present) were noted. Tumor size (\3 cm vs.
C3 cm) was also recorded.
Immunohistochemical Methods
Briefly, tissues were deparaffinized in xylene and rehy-
drated in graded alcohols and water. Endogenous
peroxidase was blocked by soaking in 3% H2O2 at 45C for
4 min. The slides were microwaved in citrate buffer (2.1 g/
L, pH 6.0) at 120C for 15 min to unmask the antigen and
were then treated with a protein-blocking reagent before
incubation at 4C overnight with primary antibodies at a
1:50 dilution, as recommended by the manufacturer. After
extensive washing, the sections were incubated with bio-
tinylated anti-mouse immunoglobulin antibodies (Zymed
Essence Co. San Francisco, CA) at a 1:20 dilution at room
temperature for 10 min and subsequently with streptavidin-
biotin peroxidase complexes at a 1:25 dilution. Reaction
products were visualized by immersing the slides in 3,30-
diaminobenzidine tetrahydrochloride. Counterstaining was
performed with hematoxylin. All series included positive
and negative controls. Negative controls were prepared by
omitting the primary antibodies, and known positive con-
trols were included in each run.
Evaluation of Immunohistochemical Data
Glut-1 expression was assessed as the percentage of the
area positive for Glut-1 staining and was graded as 1
(positive area\25%), 2 (C25%,\50%), 3 (C50%,\75%),
and 4 (C75%). Expression of p53 was determined in tumor
cells according to the degree of brown nuclear staining;
specimens were considered negative when nuclear staining
was less than 10% and positive when greater than 10%.
The Ki-67 labeling index (LI) was scored by counting at
least 1000 neoplastic cells in 10-20 fields representing
different tumor areas. All stained nuclei were considered
positive regardless of the staining intensity, and specimens
with up to 20% positively stained tumor cells were con-
sidered to have a low proliferative index, and cases with
more than 20% positively stained cells were considered to
have a high proliferative index. Regarding p16 expression,
only nuclear staining was considered to be positive and any
cytoplasmic staining present was considered to be non-
specific. Loss of p16 was defined as less than 10% of
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nuclear staining. Cyclin D1 was considered overexpressed
when 10% or more of cell nuclei were stained. In Rb
expression, only nuclear staining was considered to be
positive and any cytoplasmic staining present was consid-
ered to be nonspecific. Rb loss was defined as less than
10% of nuclear staining.
E-cadherin was regarded as lost (\25% of cytoplasmic
staining) or preserved (C25%). Epithelial growth factor
receptor (EGFR) expression was assessed as intensity of
staining from 0 to 3 and graded as normal (0 and 1) or
overexpressed (2 and 3).
Statistical Analysis
The v2 test and Fisher’s exact test were used to analyze the
association between histopathologic variables, molecular
variables, and recurrence. The time to relapse was defined
as the period from the date of surgery to the date when
relapse was diagnosed. Specific time-to-recurrence curves
were plotted using the Kaplan–Meier method, whereas the
log-rank test was used to assess the statistical significance
of differences between groups. Multivariate analyses were
performed using the Cox proportional hazards model to
identify independent prognostic factors. The criterion for
significance was p \ 0.05.
Results
Histopathology
The average tumor size was 25.9 ± 11.9 mm (range = 8–
75 mm), and 15 (27.3%) patients had a tumor size greater
than 30 mm. Twenty-five (45.5%) tumors were well dif-
ferentiated, 19 (34.5%) were moderately differentiated, and
11 (20.0%) were poorly differentiated. Ten (18.5%) tumors
showed necrosis, vascular invasion occurred in 3 (5.6%)
tumors, lymphatic vessel invasion occurred in 13 (24.1%),
and visceral pleural invasion occurred in 20 (36.4%). Eight
(14.5%) patients had tumors of at least 3 cm as well as
visceral pleural invasion tumors (Table 1).
Immunohistochemical Staining
Glut-1 expression was detected in 46 patients; 32 (58.2%)
patients were grade 1, 3 (5.5%) were grade 2, 6 (10.9%)
were grade 3, and 5 (9.1%) were grade 4. Positivity of p53
was found in 15 (27.3%) patients. Expression of Ki-67 was
observed in all patients, with 38 (69.1%) having a low LI
and 17 (30.9%) having a high LI. There was a loss of p16
in 15 (27.3%) cases and a loss of Rb in 18 (32.7%) cases.
Cyclin D1 was overexpressed in 43 (78.2%) cases, E-
cadherin was lost in 7 (13.0%) cases, and EGFR was
overexpressed in 24 (43.6%) cases (Table 2).
Association Between Histopathologic
and Molecular Factors
Glut-1 expression was significantly high in several factors
such as positive p53 (p = 0.028), high LI Ki-67 (p =
0.001), and necrosis (p = 0.001). The positivity of p53 was
correlated with high LI Ki-67 (p = 0.007) and vascular
invasion (p = 0.044). A high LI of Ki-67 was correlated
with necrosis (p = 0.001) and cyclin D1 (p = 0.030, no
expression). Loss of Rb was more frequent in patients with
T2 stage tumors (p = 0.015), with visceral pleural invasion
(p = 0.001), and with cyclin D1 (p = 0.001, no expression).
Recurrence
Median follow-up was 28.9 months and the 3-year disease-
free survival rate was 77.7%, with a mean disease-free time
of 37.9 months. Twelve patients (21.8%) had recurrent
disease and six patients (10.9%) died from disease-related
causes. Three of the 12 patients had local recurrence and
nine patients had distant recurrence. Of the 9 patients with
distant metastasis, 3 had bone metastasis, 3 had recurrence at
the contralateral lung, 1 at the liver, 1 at the brain, and 1 at
multiple sites. Table 3 shows that histopathologic factors,
including differentiation (p = 0.035), size (p = 0.046),
Table 1 Histopathologic findings in 55 resected stage I adenocarci-
noma cases
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lymphatic vessel invasion (p = 0.017), necrosis (p =
0.033), and molecular markers consisting of p53 positivity
(p = 0.046) and E-cadherin loss (p = 0.036), were signifi-
cantly associated with recurrence.
Table 4 lists the results of univariate analysis for the
prognostic significance of each histopathologic factor and
molecular marker in relation to the time to recurrence. The
log-rank test showed that the T factor, necrosis, differen-
tiation, lymphatic vessel invasion, E-cadherin loss, positive
p53, and EFGR overexpression were prognostic factors
(Fig. 1). Multivariate analysis using the Cox proportional
hazards regression model, showed that necrosis, lymphatic
vessel invasion, E-cadherin, p53, and Ki-67 were inde-
pendent prognostic factors of recurrence (Table 4).
To further stratify patients, prognostic factors, including
necrosis, lymphatic vessel invasion, E-cadherin, and p53,
which were prognostic factors in both univariate and
multivariate analyses, were chosen. Patients were then
Table 2 Immunohistochemical staining in 55 resected stage I ade-
nocarcinoma cases
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divided into two groups according to the number of risk
factors present. The low-risk group (n = 44) had fewer
than two risk factors and the high-risk group (n = 11) had
two or more risk factors. Disease-free survival rates at
3 years were 88 ± 5% for the low-risk group and
36 ± 14% for the high-risk group (p \ 0.05 by the log-
rank test) (Fig. 2).
Discussion
The prognosis for patients with cancer is divided into
tumor-, patient-, and environment-related factors and a
better understanding of the biology of tumors should
provide useful information for predicting clinical out-
comes and for individualizing treatment [9]. Because lung
cancer is a heterogeneous disease resulting from the
acquisition of multiple somatic mutations, the prognostic
role of histopathologic and molecular markers is difficult
to determine [9]. Both the differentiation of patients with
a high risk of early recurrence and the identification of
patients who may respond to adjuvant therapy are topics
of great interest and have brought about intense study in
this new era of pharmocogenomics. Although patients
with stage I NSCLC fare significantly better than those
with more advanced disease, a significant fraction of stage
I patients experience disease recurrence and die after
curative resection. Stratification of patient prognosis using
only the TNM staging system does not allow one to
differentiate patients with stage I lung cancer who are and
are not at risk of tumor recurrence.
The role of chemotherapy after surgery for stage I dis-
ease remains a subject of debate. CALGB9633, a
randomized trial that evaluated the effects of adjuvant
chemotherapy, showed a statistically significant effect in
favor of adjuvant chemotherapy for failure-free survival
and overall survival for tumors larger than 4 cm [10]. In
Japan, only patients with adenocarcinoma in the UFT
group had a significantly better survival rate than patients
with other cell types [11]. It has been demonstrated that
adjuvant therapy is not effective in all patients with stage I
disease; it is effective only in specific subsets of patients. It
is important to select a subgroup of patients with stage I
disease who might benefit from adjuvant therapy, and for
this reason investigators have attempted to pinpoint factors
that predict poor prognosis through analysis of clinical and
histopathologic factors [12–15]. Therefore, the goals of this
study were to identify these prognostic factors and to
Table 4 Univariate and






T stage 1/2 0.037 [0.05
Tumor size B3 cm/[3 cm [0.05 [0.05
Necrosis Absent/present 0.010 0.009
Differentiation Well/mod/poor 0.021 [0.05




Visceral pleural invasion Absent/present [0.05 [0.05
p16 Loss/preserved [0.05 [0.05
Rb Loss/preserved [0.05 [0.05
Cyclin D Normal/overexpressed [0.05 [0.05
E-cadherin Loss/preserved 0.006 0.026
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Fig. 1 Kaplan–Meier analysis of disease-free survival for (a) necrosis, (b) T-factor, (c) differentiation, (d) lymphatic vessel invasion, (e) p53, (f)
EGFR, and (g) E-cadherin
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evaluate the association between histopathologic and
molecular markers.
A multitude of histopathologic factors associated with
survival have been described in the literature through ret-
rospective studies. Harpole et al. [5] endeavored to define
risk factors associated with recurrence and death in 289
resected stage I lung cancer patients; vascular invasion,
visceral pleural invasion, high mitotic index, and tumor
size greater than 3 cm were identified. The degree of dif-
ferentiation of the primary tumor is known to be a
significant prognostic factor and poorly differentiated
tumors are defined as negative prognostic factors in
patients with stage I NSCLC [16]. In this study, poorly
differentiated tumors were related to high-grade Glut-1
expression and a high Ki-67 LI, which indicates that a
poorly differentiated tumor has high proliferative activity
and requires more glucose uptake for growth. The tumor
growth rate was higher in less-differentiated tumors, and
necrosis was found to be related inversely to differentiation
and associated with tumor size [9]. In the present study,
patients with tumors with necrosis had a significantly
shorter time to recurrence than patients without necrosis.
Peritumoral lymphatic vessel invasion has been dem-
onstrated to have prognostic significance for local and
distant recurrence [17]. The first step of lymph node
metastasis is cancer cell invasion of the lymphatic vessels
within the tumors; therefore, tumors that have lymphatic
vessels invasion of the tumour cells have a potential risk of
local recurrence [18]. Although data based on clinical and
histopathologic descriptions aids in dividing patients into
risk groups, there is much variation in the interpretation of
these qualitative variables. Therefore, many molecular
biological markers have been studied in lung cancer to
determine their prognostic importance. Gene copy number
and mutation analyses are now being explored in pro-
spective clinical studies in enriched populations. These
assays are very promising, but they are costly and are not
widely available. In contrast, protein expression studies by
immunohistochemistry (IHC) are rapid, reproducible, and
routinely performed in many hospitals. During the last
decade, the aggressive phenotypes of lung cancer have
been characterized by a number of molecular abnormali-
ties, so multiple algorithms were created based on relative
protein expression profiles using up to 15 factors with
possible significance. These studies showed that the pri-
mary factors associated with prognosis were p53, factor
VIII, Her2-neu, CD44, and Rb [19]. Considering these
results, markers that represent five separate oncogenic
pathways were chosen for this study: growth factor
(EGFR), cell cycle-related factors (p16, cyclinD1, Rb,
p53), metastatic adhesion factor (E-cadherin), metabolic
factor (Glut-1), and proliferation factor (Ki-67). With both
univariate and multivariate analysis, our results showed
that p53 and E-cadherin are significant prognostic factors.
Because p53 is a tumor suppressor gene that can induce
temporary growth arrest and DNA repair or apoptosis in
response to potentially oncogenic cellular stress such as
DNA damage, the impairment of cell growth control results
in uncontrolled cell proliferation [20]. However, the rela-
tionship between p53 expression and prognosis remains
unclear, even though abnormal p53 protein expression and
p53 gene mutation have been extensively investigated for
their prognostic value in early-stage resected NSCLC
patients. Some investigators have demonstrated that p53
overexpression is an independent prognostic factor in node-
negative NSCLC, although there is no difference in clinical
outcome between p53-positive and p53-negative tumors in
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Fig. 2 Analysis of disease-free
survival (a) according to the
involvement of the four
prognostic factors that were
significant in both univariate
and multivariate analysis and
(b) according to the risk group:
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protein expression is consistently higher in squamous cell
carcinoma than in adenocarcinoma, but the impact appears
greater in the latter [22, 23].
E-cadherin and catenins are components of the adherens
junction protein, with crucial roles in maintaining intercel-
lular junctions in epithelial cells; reduced E-cadherin
expression could potentially affect tumor differentiation,
metastasis, and prognosis [24, 25]. Therefore, it might be
associated with a pathologic factor of metastatic activity,
and in this study, E-cadherin expresssion is associated with
lymphatic vessel invasion (p = 0.021). Although the num-
ber of patients who demonstrated loss of E-cadherin is small,
it still represents a statistically significant prognostic factor.
D’Amico et al. [9], using the prognostic risk model for
survival, demonstrated significantly decreased survival
according to the total number of factors involved with
multivariable analysis of the entire panel of molecular
markers. Lu et al. [26] reported similar results. In their
study, they revealed that two factors were significant
negative prognostic factors and defined the patients with
two factors as high-risk. A log-rank test assessing the dif-
ference in survival was statistically significant for both
disease-specific survival and overall survival [26].
This study had limitations. First, immunohistochemical
scoring is at best a semiquantitative exercise for which no
standard criteria have yet been proposed or adopted. The
scoring methods that have been used included estimating
the grade of staining intensity, percentage of tumor cells
stained, cellular localization of the antigen, and systems
that combined these parameters. Second, more importantly,
there is confusion in the method of determining cutoffs for
dichotomizing scores in log-rank tests. Cutoffs are often
arbitrary and are sometimes selected to obtain the desired
effect using the minimum p-value approach. Therefore,
different antibodies and grading systems should also be
taken into account; the counting of positive tumor cells and
grading of staining intensity may be subject to interob-
server variability, which should be evaluated. Third, due to
the short follow-up period, some markers, if any, that
influence late recurrence would not be prognostic factors.
However, in lung cancer, most recurrence occurs within
2 years, and 3-year follow-up periods are considered
acceptable. Fourth, this study has a small number of
patients. As mentioned above, lung cancer is a heteroge-
neous disease and there is much confusion about the
evaluation of molecular markers in all stages and every cell
type of lung cancer. Therefore, even though it resulted in a
smaller number of patients, the study population was
intentionally confined to a homogeneous group of resected
stage I adenocarcinoma patients. Based on these results, it
is possible to tailor individualized therapy to stage I lung
cancer. Despite the lack of results to support adjuvant
chemotherapy in stage I diseases outside a clinical trial
setting, it is probably reasonable to consider the possibility
of adjuvant systemic chemotherapy in individual healthy
younger patients whose resected tumors exhibit poor
prognostic histologic findings and who have associated
molecular markers such as lymphatic vessel invasion,
necrosis, p53 overexpression, and E-cadherin loss.
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